Search company, investor...

Predict your next investment

Hedge Fund
northsound.com

Investments

53

Portfolio Exits

21

About North Sound Capital

North Sound Capital LLC is an employee owned hedge fund sponsor. The firm provides its services to pooled investment vehicles. It invests in the public equity markets of the United States. The firm was formerly known as DMG Advisors, LLC. North Sound Capital is based in Greenwich, Connecticut with an additional office in Denver, Colorado.

Headquarters Location

Three Greenwich Office Park

Greenwich, Connecticut, 06831,

United States

Want to inform investors similar to North Sound Capital about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest North Sound Capital News

IsoPlexis Closes $25M Series C Financing

May 14, 2019

IsoPlexis , a Branford, Conn.-based company focused on advancing single-cell biomarkers to address critical challenges in oncology & beyond, raised $25m in Series C funding. The round was led by Northpond Ventures with participation from current investors Spring Mountain Capital, Ironwood Capital, North Sound Capital, and Connecticut Innovations. Led by Sean Mackay, CEO and co-founder, IsoPlexis aims to accelerate the fight against cancer and a range of the world’s toughest diseases with its single-cell detection systems. By revealing unique immune biomarkers in small subsets of cells, the company is advancing immunotherapies and targeted therapies to a more precise & personalized stage. Its integrated systems are used globally to advance the field of single-cell biology and biomarkers. In 2018, IsoPlexis’ novel single-cell immune biomarkers accelerated insights in the field of cancer immunotherapy. Its single-cell polyfunctional strength product predicted responses of CAR engineered T cell therapy patients in blood cancers, pre-therapy, for the first time. Customers also released multiple data sets defining the quality of patient response of CAR-T, TCR-T, CRISPR edited T-cells, and more. Additionally, its systems achieved correlative data through its novel profiling of TILs and T-cell from the blood of checkpoint immunotherapy patients. IsoPlexis rapidly expanded its user base with the launch of the IsoLight system at various Cancer Centers and biopharmas in the US, Europe and China in the second half of 2018. For 2019, the company has begun to share information on new single-cell product launches to address high need areas based on data generated and published on IsoPlexis’ platform. These include: single-cell polyfunctional inflammation solutions targeted towards neuroinflammation and autoimmunity, single-cell solutions for innate & myeloid cell types that contribute to immunotherapy response, single-cell energy state assays focused on advanced metabolomics in oncology, and tumor resistance assays focused on advanced tumor signaling. In continuing its path forward, the company continues to utilize its internal application engine and its partnerships with university professors and co-founders to build innovative single-cell products addressing high need disease areas. Additionally, it will expand its global operational, manufacturing, and commercial team across US, Europe and Asia, to add to the 105 employees IsoPlexis has currently. FinSMEs

North Sound Capital Investments

53 Investments

North Sound Capital has made 53 investments. Their latest investment was in Iridia as part of their Series A - V on March 3, 2021.

CBI Logo

North Sound Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/16/2021

Series A - V

Iridia

$6M

Yes

1

11/14/2018

Series C

IsoPlexis

$25M

Yes

4

4/5/2007

Series B

Sirion Holdings

$45M

Yes

9/22/2006

Private Equity - III

Subscribe to see more

$99M

Subscribe to see more

0

6/9/2006

Unattributed VC - III

Subscribe to see more

$99M

Subscribe to see more

0

Date

3/16/2021

11/14/2018

4/5/2007

9/22/2006

6/9/2006

Round

Series A - V

Series C

Series B

Private Equity - III

Unattributed VC - III

Company

Iridia

IsoPlexis

Sirion Holdings

Subscribe to see more

Subscribe to see more

Amount

$6M

$25M

$45M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

1

4

0

0

North Sound Capital Portfolio Exits

21 Portfolio Exits

North Sound Capital has 21 portfolio exits. Their latest portfolio exit was Antares Pharma on May 24, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/24/2022

Acq - P2P

$99M

5

10/8/2021

IPO

$99M

Public

6

6/21/2012

Acquired

$99M

12/16/2011

Acq - P2P

Subscribe to see more

$99M

Subscribe to see more

10

8/18/2008

Acquired

Subscribe to see more

$99M

Subscribe to see more

0

Date

5/24/2022

10/8/2021

6/21/2012

12/16/2011

8/18/2008

Exit

Acq - P2P

IPO

Acquired

Acq - P2P

Acquired

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Sources

5

6

10

0

North Sound Capital Acquisitions

1 Acquisition

North Sound Capital acquired 1 company. Their latest acquisition was FiberNet Telecom Group on January 24, 2003.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/24/2003

Private Equity

$99M

$57.58M

Acquired

Date

1/24/2003

Investment Stage

Private Equity

Companies

Valuation

$99M

Total Funding

$57.58M

Note

Acquired

Sources

North Sound Capital Team

1 Team Member

North Sound Capital has 1 team member, including former Managing Director, Sandeep Steve Laumas.

Name

Work History

Title

Status

Sandeep Steve Laumas

BAM Elevate, and Goldman Sachs

Managing Director

Former

Name

Sandeep Steve Laumas

Work History

BAM Elevate, and Goldman Sachs

Title

Managing Director

Status

Former

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.